Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Repligen Corporation stock
Learn how to easily invest in Repligen Corporation stock.
Repligen Corporation is a medical instruments & supplies business based in the US. Repligen Corporation shares (RGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Repligen Corporation employs 1,852 staff and has a trailing 12-month revenue of around $801.3 million.
How to buy Repligen Corporation stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – RGEN. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Repligen Corporation stock price (NASDAQ: RGEN)Use our graph to track the performance of RGEN stocks over time.
Repligen Corporation shares at a glance
|Latest market close||$185.30|
|52-week range||$137.21 - $262.26|
|50-day moving average||$175.22|
|200-day moving average||$183.07|
|Wall St. target price||$225.55|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$2.79|
Buy Repligen Corporation stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Repligen Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Repligen Corporation price performance over time
|1 week (2023-01-25)||1.91%|
|1 month (2022-12-30)||9.44%|
|3 months (2022-11-01)||-0.13%|
|6 months (2022-08-01)||-12.82%|
|1 year (2022-02-01)||-8.67%|
|2 years (2021-02-01)||-10.23%|
|3 years (2020-01-31)||84.58%|
|5 years (2018-02-01)||427.62%|
Is Repligen Corporation stock undervalued or overvalued?
Valuing Repligen Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Repligen Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Repligen Corporation's P/E ratio
Repligen Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, Repligen Corporation shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Repligen Corporation's PEG ratio
Repligen Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Repligen Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Repligen Corporation's EBITDA
Repligen Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $263.3 million.
The EBITDA is a measure of a Repligen Corporation's overall financial performance and is widely used to measure a its profitability.
Repligen Corporation financials
|Revenue TTM||$801.3 million|
|Operating margin TTM||26.92%|
|Gross profit TTM||$400.8 million|
|Return on assets TTM||5.73%|
|Return on equity TTM||9.37%|
|Market capitalisation||$10.1 billion|
TTM: trailing 12 months
Repligen Corporation share dividends
We're not expecting Repligen Corporation to pay a dividend over the next 12 months.
Repligen Corporation share price volatility
Over the last 12 months, Repligen Corporation's shares have ranged in value from as little as $137.21 up to $262.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repligen Corporation's is 1.0778. This would suggest that Repligen Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Repligen Corporation overview
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Repligen Corporation in the news
Repligen (NASDAQ:RGEN) stock performs better than its underlying earnings growth over last five years
Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?
Do Options Traders Know Something About Repligen (RGEN) Stock We Don't?
Frequently asked questionsWhat percentage of Repligen Corporation is owned by insiders or institutions?
Currently 0.385% of Repligen Corporation shares are held by insiders and 93.39% by institutions. How many people work for Repligen Corporation?
Latest data suggests 1,852 work at Repligen Corporation. When does the fiscal year end for Repligen Corporation?
Repligen Corporation's fiscal year ends in December. Where is Repligen Corporation based?
Repligen Corporation's address is: Building 1, Waltham, MA, United States, 02453 What is Repligen Corporation's ISIN number?
Repligen Corporation's international securities identification number is: US7599161095 What is Repligen Corporation's CUSIP number?
Repligen Corporation's Committee on Uniform Securities Identification Procedures number is: 759916109
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert